Insider Selling: Heartflow (NASDAQ:HTFL) Director Sells 8,000 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 8,000 shares of Heartflow stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $27.32, for a total value of $218,560.00. Following the transaction, the director owned 36,413 shares of the company’s stock, valued at $994,803.16. This represents a 18.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Heartflow Trading Up 6.7%

HTFL opened at $27.74 on Monday. The firm has a market capitalization of $2.36 billion and a price-to-earnings ratio of -15.33. The firm’s fifty day moving average is $30.33. Heartflow, Inc. has a 52 week low of $25.38 and a 52 week high of $41.22.

Analysts Set New Price Targets

HTFL has been the topic of a number of recent research reports. Wells Fargo & Company began coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Stifel Nicolaus increased their price target on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. JPMorgan Chase & Co. raised their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Finally, Canaccord Genuity Group upped their target price on Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP bought a new stake in Heartflow during the third quarter valued at $164,263,000. Baillie Gifford & Co. bought a new stake in shares of Heartflow during the 3rd quarter valued at about $101,182,000. Schusterman Interests LLC acquired a new stake in Heartflow during the third quarter worth about $65,274,000. Vanguard Group Inc. lifted its holdings in Heartflow by 8.8% in the fourth quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock worth $46,066,000 after acquiring an additional 128,400 shares during the last quarter. Finally, Capital International Investors acquired a new position in Heartflow in the third quarter valued at approximately $43,671,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.